Category: clinical study retractions

Duplicate submission forces retraction of derm laser paper

jclasertherThe Journal of Cosmetic and Laser Therapy has retracted a 2014 paper by a group of South Korean researchers after determining that the authors had doubled up on their publishing odds by submitting the manuscript to a competing journal.

The article was titled “A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner’s solution in melasma patients,” and it purported to find that:

This study suggests Jessner’s peel is a safe and effective method in the early course of treatment for melasma when combined with low-fluence 1064-nm Q-switched Nd:YAG laser.

Continue reading Duplicate submission forces retraction of derm laser paper

Leading diabetes researcher corrects paper as more than a dozen studies are questioned on PubPeer

maelder
Kathrin Maedler

Prominent German diabetes researcher Kathrin Maedler has issued corrections on two papers, and told Retraction Watch she is in the process of defending the data on others.

14 of her papers have been critiqued by PubPeer commenters. The commentary, which spans from her graduate work in 2002 to a 2014 publication in Nature Medicine, includes questions about image manipulation and self-plagiarism.

Laborjournal’s blog (we have a column in their English-language publication) first flagged these suspicions in July 2014, after being approached by pseudonymous Clare Francis.

Here’s a comparison between figures in Maedler’s 2009 PLoS One paper, “Deletion of the Mitochondrial Flavoprotein Apoptosis Inducing Factor (AIF) Induces β-Cell Apoptosis and Impairs β-Cell Mass,” and one she co-authored in 2006 in Diabetes, “Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets,” via PubPeer:  Continue reading Leading diabetes researcher corrects paper as more than a dozen studies are questioned on PubPeer

A ewe-turn: Researchers lose sleep, and paper, over miscounted sheep

Suspicious sheep via John Haslam
Suspicious sheep via John Haslam

A group of Chinese cardiologists at Capital Medical University have done a quick ewe-turn, pulling a paper after mixing up both the author order and wrongly reporting how many sheep were killed in the making of this experiment.

We covered another retraction from the CMU cardiology department in September. The sheep paper was published in October.

Here’s the notice for “Mosaic tissue-engineered porcine pulmonary artery valved conduit: long-term follow-up after implantation in an ovine model”: Continue reading A ewe-turn: Researchers lose sleep, and paper, over miscounted sheep

Paper on cranberries’ health benefits retracted after researcher forges authors’ names

Image via Bruce Foster.
Image via Bruce Foster.

A paper in Food Chemistry suggesting cranberry extract has healing properties was retracted after some of the authors complained they had no idea the paper was being published.

Here’s the notice for “Phenolic composition, antioxidant properties, and endothelial cell function of red and white cranberry fruits:” Continue reading Paper on cranberries’ health benefits retracted after researcher forges authors’ names

Thalidomide paper retracted for lab error

fertstertResearchers at the University of Pittsburgh have retracted a paper on using thalidomide, which led to an estimated 10,000 birth defects by the time the drug was pulled from the market in 1961, to prevent chemo-induced sterility.

Alkylating agents, which prevent DNA replication in cells, are a commonly-used cancer treatment. Unfortunately they also damage the ovaries and testes, sometimes causing infertility. The University of Pittsburgh scientists published a paper in Elsevier journal Fertility and Sterility in 2011 that suggested thalidomide, which causes severe birth defects when used during pregnancy, might help protect ovaries during chemo.

However, according to the notice, the authors tried and failed to replicate their results. They had two separate scientists who were not authors take a look at the results; everyone agreed that the original study incorrectly reported the number of primordial follicles, the precursor to mature eggs.

Here’s the notice for “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”: Continue reading Thalidomide paper retracted for lab error

Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

JHH(Cover).inddA major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension. 

Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.

Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.

The paper, which has been cited three times, according to Thomson Scientific’s Web of Knowledge, had already been subject to a correction in 2013:  Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

AIDS denialism paper retracted after Jeffrey Beall draws attention to it

scirpA paper arguing that HIV does not cause AIDS has been retracted a few weeks after Jeffrey Beall, who tracks predatory publishers, called attention to it on his blog.

Here’s what Beall wrote about the paper on December 16:

The article is entitled “Basic Principles Underlying Human Physiology” [1], and you don’t have to be a scientist to know that it’s junk, for it is a manifestation of AIDS denialism. The conclusion’s first paragraph says,

HIV is not etiologically involved in AIDS. It is just a common retrovirus found in AIDS conjuncturally. There is only AIDS that may not be strictly associated neither to a primary immune deficiency nor to an acquired immune deficiency. Actually, heart failure represents the causal factor of AIDS and many other “primary” immune deficiencies (p. 1821).

Now, in that article’s place, this retraction, dated December 19, appears: Continue reading AIDS denialism paper retracted after Jeffrey Beall draws attention to it

Fake peer review fells two more papers

medicineThe number of papers retracted for fake peer reviews — well in excess of 100, by our count — continues to grow.

The latest to join the list are “Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials” and “Association study of TGFBR2 and miR-518 gene polymorphisms with age at natural menopause, premature ovarian failure and early menopause among Chinese Han women,” both published in 2014 in Medicine.

Here’s how both notices, signed by senior publisher Duncan A. MacRae, read: Continue reading Fake peer review fells two more papers

Retractions follow revelations of misconduct by diabetes biotech

diabetes careSeveral months after a drug company cancelled development of a potential diabetes cure because it found evidence that a biotech they had recently acquired had committed misconduct in studies of the drug, two retractions of relevant studies have appeared.

The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had

uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.

The retractions are both of papers published in Diabetes Care in May 2014. Here’s the notice for “Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial:” Continue reading Retractions follow revelations of misconduct by diabetes biotech

Stem cell study retraction produces useless notice

int j stem cellsWe don’t have much to go on here, for a retraction from the International Journal of Stem Cells. 

Here’s what we do know: Dental researchers at several universities in Egypt, including Cairo University, Future University, and Misr University published a paper together. According to the article, they gave dogs oral ulcers and then injected the ulcers with either fat-derived stem cells, bone marrow stem cells, or saline. The researchers conclude that the fat stem cells, also known as adipose derived stem cells, helped the dogs heal.

Unfortunately, we have no idea what went wrong, because the retraction notice is useless. Here in its entirety is the notice for “Adipose Stem Cells as Alternatives for Bone Marrow Mesenchymal Stem Cells in Oral Ulcer Healing”: Continue reading Stem cell study retraction produces useless notice